The changes made in the reimbursement standards for urothelial carcinoma brought joy or sadness to affected companies. A new reimbursement standard for urothelial carcinoma has been created for MSD’s ‘Keytruda inj (pembrolizumab),’ while the reimbursement standard for Roche’s ‘Tecentriq inj (atezolizumab)' has been removed from the list because it was unable to satisfy the conditional marketing approval requirements set by the Ministry of Food and Drug Safety.

The Health Insurance Review and Assessment Service conducted an opinion inquiry on the “notice on the revision of the pharmaceuticals prescribed and administered to cancer patients” that contains the content above by the 18th.